Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOVXNASDAQ:LPTXNASDAQ:THTXNYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOVXGeoVax Labs$0.93-0.3%$1.16$0.73▼$11.18$14.06M3.47558,265 shs305,682 shsLPTXLeap Therapeutics$0.38+12.0%$0.37$0.22▼$4.79$15.54M-0.17829,555 shs327,390 shsTHTXTheratechnologies$2.61-0.4%$2.02$1.12▼$3.13$120.01M0.56803,272 shs392,534 shsVORVor Biopharma$0.17+14.0%$0.70$0.13▼$1.87$21.54M-0.21699,443 shs6.14 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOVXGeoVax Labs0.00%-8.16%-9.06%-40.54%-40.54%LPTXLeap Therapeutics0.00%-20.30%+3.40%-37.67%-87.95%THTXTheratechnologies0.00%-5.42%+35.05%+59.76%+114.75%VORVor Biopharma0.00%-77.12%-78.39%-89.04%-91.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGOVXGeoVax Labs2.7596 of 5 stars3.62.00.00.02.61.71.3LPTXLeap Therapeutics2.4401 of 5 stars3.14.00.00.02.70.01.3THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/AVORVor Biopharma2.8037 of 5 stars4.20.00.00.01.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOVXGeoVax Labs 3.29Buy$11.101,099.87% UpsideLPTXLeap Therapeutics 2.25Hold$4.921,210.76% UpsideTHTXTheratechnologies 4.00Strong BuyN/AN/AVORVor Biopharma 2.40Hold$7.063,991.10% UpsideCurrent Analyst Ratings BreakdownLatest GOVX, VOR, LPTX, and THTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $0.405/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.004/16/2025GOVXGeoVax LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025GOVXGeoVax LabsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.504/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOVXGeoVax Labs$5.59M2.51N/AN/A$3.24 per share0.29LPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/ATHTXTheratechnologies$88.67M1.35N/AN/A($0.45) per share-5.80VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOVXGeoVax Labs-$25.97M-$3.65N/AN/AN/AN/A-809.87%-349.34%5/13/2025 (Estimated)LPTXLeap Therapeutics-$81.41M-$1.84N/AN/AN/AN/A-116.24%-93.18%5/12/2025 (Estimated)THTXTheratechnologies-$23.96M-$0.08N/A37.29N/A-3.75%N/A-4.31%7/9/2025 (Estimated)VORVor BiopharmaN/A-$1.70N/AN/AN/AN/AN/AN/AN/ALatest GOVX, VOR, LPTX, and THTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GOVXGeoVax Labs-$0.51N/AN/AN/A$1.75 millionN/A5/12/2025Q1 2025LPTXLeap Therapeutics-$0.38N/AN/AN/AN/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 million3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOVXGeoVax LabsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOVXGeoVax LabsN/A4.174.17LPTXLeap TherapeuticsN/A3.973.97THTXTheratechnologiesN/A1.080.97VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOVXGeoVax Labs6.09%LPTXLeap Therapeutics30.46%THTXTheratechnologiesN/AVORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipGOVXGeoVax Labs1.20%LPTXLeap Therapeutics5.40%THTXTheratechnologiesN/AVORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOVXGeoVax Labs1015.19 million8.90 millionNot OptionableLPTXLeap Therapeutics4041.44 million36.25 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableVORVor Biopharma140124.85 million65.45 millionNot OptionableGOVX, VOR, LPTX, and THTX HeadlinesRecent News About These CompaniesWhat is Wedbush's Estimate for Vor Biopharma Q1 Earnings?May 12 at 3:33 AM | americanbankingnews.comVor Biopharma's (VOR) Market Perform Rating Reiterated at JMP SecuritiesMay 12 at 2:25 AM | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for Vor Biopharma (NYSE:VOR)May 12 at 2:25 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Lowered to "Hold" Rating by Citizens JmpMay 12 at 1:15 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Cut to "Hold" at Jones TradingMay 11 at 3:35 AM | americanbankingnews.comBaird R W Downgrades Vor Biopharma (NYSE:VOR) to HoldMay 11 at 2:23 AM | americanbankingnews.comVor Biopharma's (VOR) Neutral Rating Reaffirmed at WedbushMay 11 at 2:23 AM | americanbankingnews.comStifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10 at 5:56 PM | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 10 at 12:53 AM | msn.comVor Biopharma draws downgrades on strategic reviewMay 9 at 7:17 PM | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9 at 2:16 PM | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9 at 2:16 PM | msn.com4 more biotechs cut staff amid market tumultMay 9 at 9:14 AM | biopharmadive.comBlood cancer biotech Vor Bio ends clinical work, lays off 95% of staffMay 8, 2025 | endpts.comVor Bio Winding Down Operations, Cutting Workforce, Exploring Potential SaleMay 8, 2025 | marketwatch.comVor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | finanznachrichten.deVor Biopharma stock plummets on operation wind-downMay 8, 2025 | in.investing.comVor Bio to wind down, halting cell therapy trials and shedding most staffMay 8, 2025 | fiercebiotech.comVor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Shares Bought by RA Capital Management L.P.May 3, 2025 | marketbeat.comLynx1 Capital Management LP Buys New Stake in Vor Biopharma Inc. (NYSE:VOR)April 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryShort Sellers Gave Up on These 3 Names RecentlyBy Gabriel Osorio-Mazilli | April 25, 2025View Short Sellers Gave Up on These 3 Names RecentlyAnalyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?By Nathan Reiff | May 10, 2025View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?GOVX, VOR, LPTX, and THTX Company DescriptionsGeoVax Labs NASDAQ:GOVX$0.93 0.00 (-0.27%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Leap Therapeutics NASDAQ:LPTX$0.38 +0.04 (+11.97%) Closing price 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.24%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Theratechnologies NASDAQ:THTX$2.61 -0.01 (-0.38%) Closing price 04:00 PM EasternExtended Trading$2.68 +0.08 (+2.87%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Vor Biopharma NYSE:VOR$0.17 +0.02 (+14.01%) Closing price 04:00 PM EasternExtended Trading$0.16 -0.01 (-4.35%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
